Pfizer signs three-year R&D pact to investigate Chinese herbals with Beijing institute.
This article was originally published in The Tan Sheet
Executive Summary
PFIZER SIGNS R&D AGREEMENT TO STUDY CHINESE HERBALS with the Institute of Basic Theory at the China Academy of Traditional Chinese Medicine, the company announced Jan. 9. Under the three-year agreement, Pfizer scientists will work with a Chinese team to examine and screen herbal extracts for their potential as human and animal medicines.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: